Lilly says hands off Gemzar: Drugmaker files suit to keep cancer drug off generic market
Fresh off one blockbuster patent defense, Eli Lilly and Co. mounted another last month when it filed suit to protect its billiondollar cancer drug Gemzar. The Indianapolis drugmaker sued Teva Pharmaceutical Industries Ltd. and a subsidiary, Sicor Pharmaceuticals Inc., to prevent them from selling generic versions of Gemzar, which treats several forms of cancer and comprises 9 percent of Lilly’s worldwide sales. Lilly learned in January that California-based Sicor had filed so-called “abbreviated new drug applications” with the U.S. Food…